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Risk factors for recurrent Clostridium difficile
infection (CDI) hospitalization among hospitalized
patients with an initial CDI episode: a retrospective
cohort study
Marya D Zilberberg1,2*, Kimberly Reske3, Margaret Olsen3, Yan Yan3 and Erik R Dubberke3

Abstract
Background: Recurrent Clostridium difficile infection (rCDI) is observed in up to 25% of patients with an initial CDI
episode (iCDI). We assessed risk factors for rCDI among patients hospitalized with iCDI.
Methods: We performed a retrospective cohort study at Barnes-Jewish Hospital from 1/1/03 to 12/31/09. iCDI was
defined as a positive toxin assay for C. difficile with no CDI in previous 60 days, and rCDI as a repeat positive toxin
≤42 days of stopping iCDI treatment. Three demographic, 13 chronic and 12 acute disease characteristics, and 21
processes of care were assessed for association with rCDI. Cox modeling identified independent risk factors for rCDI.
Results: 425 (10.1%) of 4,200 patients enrolled developed rCDI. Of the eight risk factors for rCDI on multivariate
analyses, the strongest three were 1) high-risk antimicrobials following completion of iCDI treatment (HR 2.95, 95%
CI 2.25-3.86), 2) community-onset healthcare-associated iCDI (HR 1.80, 95% CI 1.41-2.29) and 3) fluoroquinolones
after completion of iCDI treatment (HR 1.56, 95% CI 1.63-2.08). Other risk factors included gastric acid suppression,
≥2 hospitalizations within prior 60 days, age, and IV vancomycin after iCDI treatment ended.
Conclusions: The rCDI rate was 10.1%. Recognizing such modifiable risk factors as certain antimicrobial treatments
and gastric acid suppression may help optimize prevention efforts.
Keywords: C. difficile, Risk factors, Recurrence

Background
Over the past decade Clostridium difficile infection (CDI)
has increased in both frequency and severity in the US
and abroad. A study from Quebec identified a 5-fold rise
in the incidence of hospitalizations with CDI over 13 years,
accompanied by a doubling in the risk of complicated disease [1]. Similarly, multiple US-based studies have reported a more-than-doubling of hospitalizations with a
CDI diagnosis between 2000 and 2005 [2,3]. These numbers have continued to rise through 2009, albeit less rapidly [4]. Much of this growth is thought to be due to the
recent emergence of the hypervirulent epidemic strain of
C. difficile, BI/NAP1/027. A fluoroquinolone-resistant
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toxin overproducer, this strain has now been detected in
most of the states in the US, in North America, Europe
and beyond [5].
One of the most challenging aspects of CDI is its propensity to recur. Both metronidazole and vancomycin,
first-line therapies recommended in the joint evidencebased practice guideline from the Society of Healthcare
Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA), have exhibited unacceptably high rates of recurrence [6]. Indeed, a recent
meta-analysis has found that CDI recurs in 13% – 50%
of all patients after an initial episode, and in the setting
of a randomized controlled trial, the recurrence rate was
25% [7-9].
Recurrent CDI (rCDI) is a cause of much morbidity,
and its economic impact is likely substantial. Several
studies have identified important risk factors for rCDI,
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including advanced age, chronic renal insufficiency, elevated white blood cell count, low serum albumin, use of
proton pump inhibitors (PPI), and continued use of
systemic antimicrobials during the initial CDI episode
(iCDI) [7,10-13]. However, a meta-analysis identified
major gaps in our understanding of the risk factors for
CDI recurrence [7]. Although the authors found concomitant antimicrobials, gastric acid suppressants and
older age to be strongly predictive of rCDI, other factors,
including iCDI treatment and specific non-CDI antimicrobials, could not be evaluated adequately due to the
lack of robust data. Additionally, most studies have
focused on the factors immediately preceding rCDI onset, ignoring the possibility that factors present at or
near the onset of the iCDI episode may also impact this
risk. In fact, recent data suggest that the burden of
community-onset healthcare-facility associated (COHCFA) CDI is much higher than previously appreciated,
and poses an additional risk pool for inpatient exposure
[14,15]. Since CO-HCFA implies an ongoing exposure to
the healthcare system, it may itself be a marker for a
recurrence.
A precise understanding of who is likely to recur is an
important clinical question for two reasons. First, if
there are modifiable exposures that increase this risk,
knowing what they are may aid clinicians in avoiding
them. Second, if patient characteristics not subject to
modification predispose to rCDI, recognizing them may
help target preventive measures more effectively. In
order to define more fully the risk factors for rCDI, we
conducted a single center retrospective cohort analysis
among patients hospitalized with an iCDI episode.

Methods
This study was approved by the Washington University
Institutional Review Board, and its conduct was in compliance with the Helsinki Declaration.
Cohort definition

We conducted a retrospective cohort study of all adult
(age ≥18 years) patients with an inpatient episode of
iCDI at Barnes-Jewish Hospital (BJH) between January 1,
2003, and December 31, 2009. An episode of CDI was
defined as a positive toxin assay (C. DIFFICILE TOX
A/B II from Techlab, Blacksburg, VA, USA) for C. difficile.
Because the hospital laboratory performs a test for C.
difficile only if the treating physician suspects CDI and
if the stool is unformed, all patients with positive toxin
results were considered to be CDI case patients. The
first episode of CDI during the study period in the absence of any CDI in the prior 60 days was defined as
the iCDI, and patients were included only once. Patients were excluded if they died during or were discharged to hospice from the iCDI hospitalization.
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All included patients were followed for 42 days from
the date of the end of iCDI treatment or until rCDI onset, defined as a repeat positive toxin within this time
frame. Initial CDI cases were categorized according to
published surveillance definitions as community-onset
healthcare facility-associated (CO-HCFA) (indeterminate CDI cases were grouped with CO-HCFA), healthcare facility-onset (HCFO), and community-associated
(CA) [16].
Data sources

Demographic and clinical data were derived from BJH
Medical Informatics databases and the BJH electronic
medical records. The data available from the Informatics
databases included C. difficile toxin assay results and
date of stool collection; patient demographics; dates
of admission and discharge; discharge disposition; admission location; ICD-9-CM diagnosis (used to define
underlying comorbidities in the year prior and during
the index hospitalization) and procedure (assessed only
during the index hospitalization) codes; dates of ICU
stays; start and stop dates of all inpatient CDI treatments, gastric acid suppressors and antimicrobials; and
white blood cell count, hemoglobin, serum creatinine,
and serum albumin levels on admission and at the time
of positive C. difficile toxin assays from the index admission and all readmissions in the 42 days after iCDI treatment end. The BJH medical records included data on
antimicrobials and CDI treatments the patient received
as an outpatient within the BJH system, and whether a
readmission was for CDI. In addition, admission and
discharge summaries were reviewed for all included hospitalizations to help determine whether the patient had
a history of CDI at another healthcare facility or as
an outpatient.
Statistical analyses

The exposure interval was divided into three periods: 1)
from hospital admission until diagnosis of iCDI, 2) from
the time of diagnosis of iCDI until the end of its treatment, and 3) from the end of iCDI treatment until the
onset of recurrence or until the end of the 42-day monitoring period for recurrence. We compared patients with
rCDI to those without rCDI based on their characteristics
in these time periods. Cox proportional hazards modeling
was used to determine variables associated with at least
one episode of rCDI on univariate analysis. Antimicrobials
were categorized based on association with CDI as highrisk (cephalosporins, aminopenicillins, and clindamycin),
low-risk (aminoglycosides, beta lactamase inhibitors, carbepenems, daptomycin, doxycycline, linezolid, macrolides,
rifampin, rifaximin, and tigecycline), fluoroquinolones
(>90% was ciprofloxacin), and intravenous vancomycin
[17,18]. Gastric acid suppressors (histamine receptor 2
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blockers [HR2B] and proton pump inhibitors [PPI]),
choice and duration of iCDI treatment, and iCDI severity,
as defined by the SHEA/IDSA Clinical Practice Guidelines
for CDI, were also assessed as potential risk factors for
rCDI [6].
We employed extended Cox proportional hazards
modeling to determine independent risk factors for at
least one episode of rCDI, with variable selection according to the methodology of Hosmer-Lemeshow [19]. Variables eligible for inclusion in the multivariable models
were those associated with increased risk of rCDI from
the literature or those with clinical or biologic plausibility, and those with p-values <0.20 in the univariate analyses. Antimicrobial exposures from the end of CDI
treatment until rCDI or 42 days were analyzed as timedependent variables. Backward stepwise selection was
used to arrive at the best-fitting and most parsimonious
model. All relevant 2-way interactions were tested after
selection of the main effects, and included in the final
models only if they were significant at the alpha ≤0.05.
The proportional hazards assumption was verified by
assessing the parallel nature of curves in log-log plots.
The appropriate functional formats of continuous variables were determined by examining nonparametric regression (smoothing) plots with a restricted cubic spline
function. To facilitate interpretation of results, the hazard ratios for the piecewise linear spline variable (fluoroquinolone exposure while on CDI treatment) compared
the hazards of developing CDI for values between the
75th and the 25th percentiles of the variable [20]. To assess the importance of time dependency for antimicrobial exposures that occur after CDI treatment, these
exposures included in the final model were also analyzed
in a time-independent fashion.
All analyses were performed in SAS version 9.3 (SAS
Institute, Cary, NC) and R (R Foundation, Vienna,
Austria) [21]. All statistical testing was two-tailed with
significance set at the alpha level ≤ 0.05.

Results
Among the 4,200 patients enrolled with iCDI, 425 (10.1%)
had at least one rCDI identified. Those with a recurrence
were older (median age 64.8, range 18.3 – 98.2, vs. 61.6,
range 18.0 – 102.4), and had a greater comorbidity burden, as evidenced by the higher Charlson score than those
without (Table 1). Of the specific comorbidities, diabetes
mellitus was more prevalent in the rCDI group than in
the group without rCDI. Notably, prior exposure to the
healthcare system was more likely among those with rCDI
than those without. Persons with rCDI were nearly twice
as likely to fit the surveillance definition for CO-HCFA
CDI during their initial episode (39%) as those without
rCDI (22%, p < 0.001). Consistent with this, patients with
rCDI had a higher frequency of at least one inpatient
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admission within 60 days prior to the iCDI episode (53%
vs. 39%, p < 0.001), as well as a higher risk for multiple recent hospitalizations than those without rCDI (Table 1).
The iCDI admission laboratory data did not differ substantively between the groups.
There were several differences between patients with
and those without rCDI with respect to exposure to
medications known to raise the risk of CDI (Table 2).
Nearly ¾ of all patients in each group were on at least
one antimicrobial at the onset of their iCDI. There were
no differences in antibiotics considered to be “high-risk”
for causing CDI between the rCDI and non-rCDI
groups. Conversely, antimicrobials designated as “lowrisk” for CDI were used with lower frequency in patients
with (22%) compared to those without rCDI (28%,
p = 0.02). Fluoroquinolone treatment was more prevalent
during the iCDI onset among those with rCDI (28%)
than those without (23%, p = 0.02). Furthermore, patients with rCDI who used gastric acid suppressors were
nearly twice as likely as those without to be started on
one within 24 hours of the iCDI diagnosis (Table 2).
Although there were no differences in the treatment regimen aimed at the iCDI episode, patients who developed
rCDI were more frequently started on such high-risk medications as gastric suppressors and non-CDI antimicrobials,
regardless of their designation as high- or low-risk, after
the onset of iCDI (Table 2). Those with subsequent rCDI
were more likely to be discharged to a healthcare facility
following the iCDI hospitalization than those without
rCDI, though this difference did not reach statistical significance. Following the hospitalization with iCDI, patients
with a subsequent rCDI were also more likely to be readmitted to the hospital both before and/or after the end
of the iCDI treatment (Table 3).
In a multivariate Cox proportional hazards model,
where we examined 49 potential covariates for their impact on the risk of rCDI, eight factors emerged as predictive of a future episode of rCDI (Table 4). In addition
to age, case status of iCDI designation of CO-HCFA was
strongly associated with rCDI, increasing its risk by 80%
(HR 1.80, 95% CI 1.41 to 2.29). In a similar vein, having
had two or more inpatient hospitalization within 60 days
prior to the onset of CDI was associated with an increased risk of rCDI (HR 1.40, 95% CI 1.04-1.89). A
number of modifiable risk factors also predicted the risk
of rCDI. They included initiation of gastric acid suppressors at the time of iCDI diagnosis (HR 1.36, 95% CI
1.004 to 1.85), and cumulative exposure to fluoroquinolones while on iCDI therapy (HR 1.45, 95% CI 1.09 to
1.41). Exposure to fluoroquinolones (HR 1.56, 95% CI
1.16 to 2.08), IV vancomycin (HR 1.45, 95% CI 1.09 to
1.92), and high-risk antimicrobials (HR 2.95, 95% CI
2.25 to 3.86) at any time t after the end of iCDI therapy
ended also increased the risk of rCDI. Demonstrating
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Table 1 Patient characteristics and treatments at hospital admission involving the initial CDI episode
Patient characteristics

Patients who developed rCDI

Patients who did not develop rCDI

Hazard ratio

(n = 425)

(n = 3775)

95% CI

64.8 (18.3 – 98.2)

61.6 (18.0 –102.4)

1.01 (1.01 – 1.02)

210 (49)

1824 (48)

1.05 (0.87 – 1.27)

Demographics
Age, years (median[range])
Gender: female
Comorbiditiesa
40 (9)

328 (9)

1.12 (0.81 – 1.55)

108 (25)

854 (23)

1.23 (0.99 – 1.53)

Peripheral vascular disease

34 (8)

269 (7)

1.13 (0.79 – 1.60)

Cerebrovascular disease

41 (10)

256 (7)

1.51 (1.10 – 2.09)

Chronic renal failure

21 (5)

190 (5)

0.98 (0.64 – 1.53)

Dementia

5 (1)

23 (1)

1.83 (0.76 – 4.41)

Myocardial infarction
Congestive heart failure

116 (27)

912 (24)

1.18 (0.95 – 1.46)

Rheumatologic disease

18 (4)

146 (4)

1.11 (0.69 – 1.78)

Peptic ulcer disease

20 (5)

154 (4)

1.18 (0.75 – 1.85)

Mild liver disease

17 (4)

201 (5)

0.81 (0.50 – 1.32)

Moderate to severe liver disease

12 (3)

134 (4)

0.86 (0.48 – 1.53)
1.32 (1.08 – 1.62)

Chronic obstructive pulmonary disease

Diabetes

135 (32)

975 (26)

Paraplegia or hemiplegia

12 (3)

78 (2)

1.40 (0.79 – 2.45)

Any malignancy (excluding leukemia/lymphoma)

83 (20)

770 (20)

0.99 (0.78 – 1.25)

Leukemia or lymphoma

78 (18)

660 (18)

1.05 (0.82 – 1.34)

Metastatic solid tumor

56 (13)

449 (12)

1.19 (0.90 – 1.58)

HIV/AIDS

10 (2)

66 (2)

1.30 (0.70 – 2.44)

0-2

223 (53)

2182 (58)

Ref

3-5

117 (28)

922 (24)

1.27 (1.01 – 1.59)

85(20)

671 (18)

1.32 (1.03 – 1.69)

HCFO/HCFA

203 (48)

2332 (62)

Ref

CA or unknown

57 (13)

597 (16)

1.07 (0.79 – 1.43)

CO/HCFA, indeterminate, or non- BJH HCFA

165 (39)

846 (22)

2.17 (1.76 – 2.66)

109 (26)

1019 (27)

0.97 (0.78 – 1.21)

0

200 (47)

2313 (61)

Ref

1

150 (35)

1021 (27)

1.70 (1.37 – 2.10)

75 (18)

441 (12)

1.96 (1.50 – 2.55)

52 (12)

522 (14)

0.94 (0.70 – 1.25)
0.92 (0.68 – 1.26)

Charlson composite score

>=6
Case statusb

Admitted from another healthcare facility
Number of inpatient admissions in previous 60 days

2+
Baseline laboratory data

c

Low albumin at admission
Low WBC at admission

44 (10)

420 (11)

High WBC at admission

236 (56)

2122 (56)

0.86 (0.66 – 1.12)

Low hemoglobin at admission

182 (43)

1572 (42)

1.09 (0.90 – 1.32)

High creatinine at admission

108 (25)

947 (25)

1.04 (0.84 – 1.30)

Low creatinine clearance

218 (51)

1636 (43)

1.43 (1.18 – 1.73)

rCDI = recurrent C. difficile infection.
a
Comorbidities diagnosed within previous 1 year (identified by ICD-9-CM diagnosis codes.
b
HCFO = health care facility onset; HCFA = healthcare facility-associated; CA = community acquired; CO = community onset. Case she status for 6 patients’ was
unknown: 1 among those who developed rCDI and 5 among those who did not.
c
The following threshold values defined “high” and “low” levels: albumin <2.5 g/dL; WBC low <3.8*103/mm3; WBC high >9.8*103/mm3; hemoglobin <10.0 g/dL;
creatinine >1.5 ug/dL; creatinine clearance <70 mL/min. WBC = white blood cells.
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Table 2 Processes of care at the onset of and treatment for the initial CDI hospitalization
Patients who developed rCDI

Patients who did not develop rCDI

Hazard ratio

(n = 425)

(n = 3775)

95% CI

Low albumin

50 (12)

548 (15)

0.84 (0.63 – 1.13)

Low WBC

64 (15)

635 (17)

0.99 (0.82 – 1.20)

High WBC

247 (58)

2027 (54)

1.23 (1.01 – 1.49)

Low hemoglobin

218 (51)

1985 (53)

0.96 (0.79 – 1.16)

High creatinine

99 (23)

862 (23)

1.08 (0.86 – 1.35)

Patient characteristics
Laboratory results iCDI onset

Relevant medications present at iCDI onset
Any antimicrobial

314 (74)

2729 (72)

1.10 (0.88 – 1.36)

Low risk antimicrobial(s)a

95 (22)

1058 (28)

0.76 (0.60 – 0.95)

High risk antimicrobial(s)b

174 (41)

1490 (40)

1.07 (0.88 – 1.29)

Fluoroquinolone

120 (28)

861 (23)

1.29 (1.05 – 1.60)

IV vancomycin

130 (31)

1321 (35)

0.86 (0.70 – 1.05)

Gastric acid suppressor, any

310 (73)

2850 (76)

0.91 (0.73 – 1.12)

New gastric acid suppressor

54 (13)

255 (7)

1.87 (1.41 – 2.49)

Any antibiotic first dose after CDI

278 (65)

1622 (43)

2.47 (2.02 – 3.02)

Low risk antimicrobial(s) first dose after CDIa

141 (33)

710 (19)

2.09 (1.71 – 2.56)

High risk antimicrobial(s) first dose after CDIb

150 (35)

714 (19)

2.30 (1.89 – 2.81)

Fluoroquinolone first dose after CDI

124 (29)

703 (19)

1.69 (1.37 – 2.09)

IV vancomycin first dose after CDI

115 (27)

337 (12)

2.61 (2.11 – 3.23)

Relevant medications received following iCDI onset

Initial CDI treatment
Metronidazole alone

323 (76)

2841 (75)

Reference

Oral vancomycin alone

16 (4)

104 (3)

1.32(0.80 – 2.18)

Metronidazole and oral vancomycin

86 (20)

829 (22)

0.95 (0.75 – 1.20)

iCDI = initial episode of C. difficile infection, rCDI = recurrent C. difficile infection.
a
Low risk antimicrobials included aminoglycosides, betalactamase inhibitors, carbepenems, daptomycin, doxycycline, linezolid, macrolides, penicillinase inhibitors,
rifampin, rifaximin, and tigecycline.
b
High risk antimicrobials included all cephalosporins, clindamycin, and penicillins.

the importance of time dependency of concomitant antimicrobials started after CDI treatment ended, when
post-CDI treatment antimicrobials were modeled in a
time independent fashion, their association with rCDI
decreased significantly (Table 4).

Discussion
We have identified eight discrete independent risk factors for recurrent CDI. Although some characteristics,
such as age, cannot be altered, several of them constitute
modifiable exposures. New gastric acid suppression and
concomitant antimicrobial exposures were associated
with increased hazards of developing recurrent CDI. Reducing these exposures could potentially decrease the
risk of recurrent CDI. This may serve as yet another reason for institutions to engage in aggressive antimicrobial
stewardship programs.
Prior investigations have reported advanced age, chronic
renal insufficiency, elevated white blood cell count, low

serum albumin, use of PPI and H2RB, as well as continued
use of systemic antimicrobials to be important risk factors
for rCDI [7,10-13,22]. Our results are in general agreement with these prior data. Gastric acid suppressors have
garnered a particular interest with respect to their impact
on iCDI and rCDI incidence. Specific to recurrent disease,
a recent meta-analysis substantiated this concern, finding
a more-than doubling of the risk of rCDI in the setting of
these drugs [7]. At the same time, it is unclear whether
both PPIs and H2RBs are associated with the risk of rCDI,
or whether one is a more likely culprit than the other. For
example a meta-analysis by Kwok and colleagues implicated PPIs but not H2RBs in a 2-fold rise of rCDI incidence [23]. Similarly, Tleyjeh et al. in a meta-analysis of 33
studies focusing specifically on H2RB exposure reported a
smaller, albeit still significant, association between receiving H2RBs and development of CDI [24]. Both metaanalyses suggested that gastric protection in conjunction
with antibiotic administration carries a higher risk of CDI
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Table 3 Outcomes following initial CDI hospitalization
Patients who
developed rCDI

Patients who did
not develop rCDI

Hazard ratio

(n = 425)

(n = 3775)

95% CI

Discharged to a healthcare facility

130 (31)

1029 (27)

1.18 (0.96 – 1.45)

0.11

Inpatient readmission(s) before end of iCDI treatment

48 (11)

241 (6)

1.76 (1.30 – 2.37)

<.001

Inpatient readmission(s) after end of iCDI treatment

126 (30)

857 (23)

1.31 (1.07 – 1.62)

0.01

Patient characteristics

p-value

iCDI = initial episode of C. difficile infection, rCDI = recurrent C. difficile infection.

development than exposure to PPIs or H2RBs alone
[23,24]. In our study, we examined gastric acid suppressors as a single category because our prior work, including
preliminary analyses for this study (data not shown), has
consistently found no difference in the associations between these two classes of medications and CDI [17,18].
Whether gastric acid suppression is truly an independent
risk factor for CDI or a marker for patients at risk for CDI
remains unknown [6].
A large body of evidence also ties concomitant use of
non-CDI antimicrobials to an increased risk of a recurrence [7,17,18,25]. We found that high-risk antimicrobials
raise the risk for rCDI, particularly when administered after
the completion of iCDI treatment. We have also confirmed
previous findings that link exposure to such specific antimicrobials as IV vancomycin and fluoroquinolones to the

risk for CDI incidence [17,18,26]. The BI/NAP1/027 strain
has been associated with fluoroquinolone exposures, and
may be more likely to cause rCDI than other strains of
C. difficile [27]. Consequently, it is possible that fluoroquinolone exposure is a marker for CDI specifically due to
this strain. For IV vancomycin, however, this association
may represent not a causal relationship, but rather a
marker for higher illness severity and, thus, confounding
by indication.
We were also able to demonstrate the importance of
timing of antimicrobial exposure after the end of CDI
treatment. When modeled as time dependent variables,
high-risk antimicrobials, fluoroquinolones, and IV
vancomycin were all associated with rCDI. When modeled as time independent variables, the hazards of rCDI
associated with high-risk antimicrobials dropped from

Table 4 Cox proportional hazards multivariable model examining risk factors for recurrent CDI
Patient characteristics
Risk factor

Antimicrobials after iCDI treatment modeled
as time dependent variables
Hazard ratio

95% CI

Antimicrobials after iCDI treatment modeled
as time independent variables
Hazard ratio

95% CI

At admission to the hospital
CDI case status
HO CDI

Ref

Ref

COHCFA CDI

1.80

1.41-2.29

1.78

1.39-2.27

CA CDI

1.30

0.95-1.80

1.25

0.91-1.72

Number of hospitalizations in previous 60 days
None

Ref

1

1.25

0.97-1.61

1.27

0.99-1.64

>1

1.40

1.04-1.89

1.46

1.08-1.96

Age (per 1 year)

1.01

1.00-1.02

1.01

1.00-1.02

Gastric acid suppression

1.36

1.00-1.85

1.40

1.03-1.90

Cumulative fluoroquinolone exposurea

1.24

1.09-1.41

1.42

1.25-1.61

2.95c

2.25-3.86

1.86

1.42-2.42

Fluoroquinolone

c

1.56

1.63-2.08

0.86

0.64-1.15

IV vancomycin

1.45c

1.09-1.92

1.05

0.80-1.39

At the onset or during treatment of iCDI

Following completion of iCDI treatment
High risk antimicrobialb

iCDI = initial episode of C. difficile infection.
a
Cumulative fluoroquinolone exposure was modeled as a three node spline.
b
High risk antimicrobials included all cephalosporins, clindamycin, and penicillins.
c
Exposure at any time t.
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2.95 (2.25-3.86) to 1.86 (1.42-2.42), and fluoroquinolones
and IV vancomycin were no longer associated with
rCDI. Intuitively, this makes sense. An antimicrobial
should not increase the risk of rCDI after CDI treatment
has ended until the patient is exposed to the antimicrobial. Not modeling antimicrobials as time dependent variables after CDI treatment has ended dilutes the
association with rCDI, since the days not on these drugs
are included in the model.
A direct relationship between CO-HCFA status and
iCDI and rCDI development is a newer finding [15].
Namely, the CO-HCFA designation of the iCDI episode
is associated with at least a 25% and as much as a 2-fold
increase in the risk of rCDI. A likely mechanism relates
to the fact that CO-HCFA defines a population of patients who is likely sicker as evident by recent hospitalizations, and more likely to be exposed to antimicrobials.
However, CO-HCFA CDI remained an independent risk
factor when controlling for recent hospitalizations.
It is worth noting that the recurrence rate we observed
in the current study is at the lower end of what has been
reported previously. For example, a recent meta-analysis
by Garey et al. examined the literature on risk factors for
rCDI [7]. In the 12 studies meeting the inclusion criteria,
the rates of recurrence ranged from 13% to 50%. More
current data from randomized controlled trials suggest
that CDI is likely to recur in approximately 25% of the
patients treated for iCDI with vancomycin [8,9]. A potential explanation for the lower rCDI rate in our study
compared to others is how cases of CDI were identified.
Most stools submitted for C. difficile testing at the BJH
microbiology laboratory come from inpatients and the
emergency room. A minority of specimens come from
outpatients or affiliated skilled nursing facilities. It is
likely that milder cases of rCDI were missed because the
patient did not require care in an emergency room or
need to be admitted. Therefore, the rCDI in this study
may consist of more clinically important episodes, occurring in sicker patients, many of whom required an
admission or evaluation in the emergency department.
It is possible that patients who resided outside the St.
Louis metropolitan area would not be likely to return to
BJH for testing for a recurrence. To examine the impact
of this potential loss to follow up, we performed a sensitivity analysis of rCDI risk factors by excluding all patients who resided beyond the greater St. Louis postal
code. After excluding the 1230 (31.1%) patients with
iCDI who met this criterion, the rCDI risk factors and
their hazard ratios did not change appreciably (data not
shown). This suggested that our results were not biased
by including these patients.
Conversely, rCDI in randomized trials may be subject
to a detection bias. Patients in trials are prospectively
monitored for recurrent diarrhea and instructed to seek

Page 7 of 8

testing if it occurs. Even if the patient’s symptoms are
not from CDI, the person may test positive for CDI as
many patients continue to shed C. difficile in stool after
cessation of CDI treatment [28].
Our study has some limitations. As a retrospective observational study it is prone to several forms of bias,
most notably a selection bias. To mitigate this, we enrolled all consecutive patients meeting our enrollment
criteria. To avoid misclassification of the main outcome
variable, we applied a stringent case definition to CDI,
which included a positive toxin assay. Although confounding is an issue with observational data, we adjusted
for all the available relevant potential confounders in the
regression model. However, the possibility of residual
confounding remains. The biggest limitation, however, is
its generalizability, since the data reflected patients and
treatment patterns at an urban academic medical center
with a large referral base, and may not have mirrored
those of institutions with different characteristics or patients with iCDI diagnosed and managed completely in
the outpatient setting. Additionally, many of the patients
who resided outside the St. Louis metropolitan area may
not have had their specimens retested at the BJH laboratory. After excluding these patients from the analysis as
part of a sensitivity analysis, neither the rCDI hazard ratios nor the rCDI risk factors were majorly impacted in
the overall cohort.

Conclusion
In summary, we have demonstrated that a number of
modifiable factors exist whose presence raises the risk
for developing rCDI. Avoiding such exposures as nonCDI antimicrobial treatment and gastric acid suppressors may go a long way toward attenuating the burden
of rCDI. On the other hand recognizing CO-HCFA and
advanced age as predispositions to rCDI should serve
patients and clinicians well by highlighting the importance of targeting these populations for more aggressive
prevention efforts.
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